Ascentage Pharma Group International AAPG
Ascentage Pharma Group International (Nasdaq: AAPG) is an oncology drug developer. Its lead program, Olverembatinib (HQP1351), is in Phase 3 for Ph+ ALL (POLARIS-1), previously treated CML-CP (POLARIS-2), SDH-deficient GIST (POLARIS-3). Its next catalyst on record is Lisaftoclax: Pursue inclusion in China NRDL (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Lisaftoclax — Pursue inclusion in China NRDL (2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Olverembatinib (HQP1351) | Ph+ ALL, CML-CP, SDH-deficient GIST (global registrational Phase 3; NMPA-approved in CML in China) | small molecule | Phase 3 |
| Lisaftoclax (APG-2575) | CLL/SLL (GLORA, GLORA-2), AML (GLORA-3), HR-MDS (GLORA-4); NMPA-approved in R/R CLL/SLL in China | small molecule | Phase 3 |
| Lisaftoclax (APG-2575) | Multiple myeloma, AML/MDS combinations (Ph1b/2) | small molecule | Phase 2 |
| Alrizomadlin (APG-115) | MDM2-p53 inhibitor, solid/heme tumors | small molecule | Phase 2 |
| Pelcitoclax (APG-1252) | Bcl-2/Bcl-xL inhibitor | small molecule | Phase 1 |
| APG-2449 | FAK/ALK/ROS1 inhibitor | small molecule | Phase 1 |
| APG-5918 | EED inhibitor (PRC2) | small molecule | Phase 1 |
| APG-3288 | R/R B-cell malignancies (BTK degrader) | small molecule | Phase 1 |
Recent results and decisions
- Nov 5, 2026positive APG-5918 demonstrated ORR of 44.7% (65.0% at 600 mg QD) with manageable safety in heavily pretreated R/R TCL patients in first-in-human Phase 1 trial.
APG-5918 demonstrated encouraging antitumor activity and a manageable safety profile in patients with heavily pretreated R/R TCLs, supporting 600 mg QD as the recommended Phase 2 dose.
Filing - Nov 5, 2026positive Olverembatinib plus lisaftoclax achieved 90% ORR with deep remissions and CNS penetration in pediatric R/R Ph+ ALL (Phase Ib).
The overall response rate (ORR) reached 90.0% (9/10) with combination therapy, and all responders achieved CR. The measurable residual disease (MRD)-negative rate was 69.2% (9/13), with efficacy also observed in patients harboring baseline ABL1 KD mutations.
Filing - Nov 5, 2026mixed Olverembatinib, lisaftoclax, and azacitidine triplet regimen achieved 30% ORR in venetoclax-failed R/R AML patients (Phase Ib).
Among 20 evaluable patients treated with olverembatinib, lisaftoclax and AZA, the overall response rate (ORR; CR+ CRi, 15%; morphologic leukemia-free state [MLFS], 10%; PR, 5%) was 30% (95% CI, 11.9%-54.3%).
Filing
6 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Astrazeneca PLC AZN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Guardant Health, Inc. GH
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.